The BH3-only protein BID impairs the p38-mediated stress response and promotes hepatocarcinogenesis during chronic liver injury in mice

Hepatology

Volumn 62, Issue 3, 2015, Pages 816-828

  Orlik, Johanna ^a   Schüngel, Sven ^a   Buitrago Molina, Laura Elisa ^a   Marhenke, Silke ^a   Geffers, Robert ^b   Endig, Jessica ^a   Lobschat, Katharina ^a   Rössler, Stephanie ^c   Goeppert, Benjamin ^c   Manns, Michael P ^a   Gross, Atan ^d   Vogel, Arndt ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEME OXYGENASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BID; PROTEIN P53; BID PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELLULAR STRESS RESPONSE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DNA DAMAGE; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER INJURY; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CELL SURVIVAL; CELL TRANSFORMATION; CYTOLOGY; DISEASE MODEL; EXPERIMENTAL LIVER NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; KNOCKOUT MOUSE; LIVER CELL; LIVER FAILURE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; RANDOMIZATION; REFERENCE VALUE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANALYSIS OF VARIANCE; ANIMALS; APOPTOSIS; BH3 INTERACTING DOMAIN DEATH AGONIST PROTEIN; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HEPATIC INSUFFICIENCY; HEPATOCYTES; LIVER NEOPLASMS, EXPERIMENTAL; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RANDOM ALLOCATION; REFERENCE VALUES;

EID: 84939652936     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27888     Document Type: Article

References (39)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, france: International Agency for Research on Cancer; 2013. Available at: http://globocan.iarc.fr. Accessed May 30, 2015.
2. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol 2014;109:542-553.
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011;365:1118-1127.
4. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-8607.
5. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
6. Chiu CT, Yeh TS, Hsu JC, Chen MF. Expression of Bcl-2 family modulated through p53-dependent pathway in human hepatocellular carcinoma. Dig Dis Sci 2003;48:670-676.
7. Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, Muller M, et al. Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol 2006;28:25-32.
8. Hussein MR, Al-Badaiwy ZH, Guirguis MN. Analysis of p53 and bcl-2 protein expression in the non-tumorigenic, pretumorigenic, and tumorigenic keratinocytic hyperproliferative lesions. J Cutan Pathol 2004;31:643-651.
9. Pizem J, Marolt VF, Luzar B, Cör A. Proliferative and apoptotic activity in hepatocellular carcinoma and surrounding non-neoplastic liver tissue. Pflugers Arch 2001;442(6 Suppl 1):R174-R176.
10. Sieghart W, Losert D, Strommer S, Cejka D, Schmid K, Rasoul-Rockenschaub S, et al. Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol 2006;44:151-157.
11. Takehara T, Liu X, Fujimoto J, Friedman SL, Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001;34:55-61.
12. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, et al. CD95 promotes tumour growth. Nature 2010;465:492-496.
13. Pierce RH, Vail ME, Ralph L, Campbell JS, Fausto N. Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. Am J Pathol 2002;160:1555-1560.
14. Qiu W, Wang X, Leibowitz B, Yang W, Zhang L, Yu J. PUMA-mediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology 2011;54:1249-1258.
15. Weber A, Boger R, Vick B, Urbanik T, Haybaeck J, Zoller S, et al. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010;51:1226-1236.
16. Baumgartner F, Villunger A. Apoptosis: a barrier against cancer no more? Hepatology 2011;54:1121-1124.
17. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998;94:491-501.
18. Bai L, Ni HM, Chen X, DiFrancesca D, Yin XM. Deletion of Bid impedes cell proliferation and hepatic carcinogenesis. Am J Pathol 2005;166:1523-1532.
19. - mice. Cell Death Differ 2013;20:869-877.
20. Grompe M, Lindstedt S, al-Dhalimy M, Kennaway NG, Papaconstantinou J, Torres-Ramos CA, et al. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 1995;10:453-60.
21. Lindblad B, Lindstedt S, Steen G. On the enzymic defects in hereditary tyrosinemia. Proc Natil Acad Sci U S A 1977;74:4641-4645.
22. Buitrago-Molina LE, Marhenke S, Longerich T, Sharma AD, Boukouris AE, Geffers R, et al. The degree of liver injury determines the role of p21 in liver regeneration and hepatocarcinogenesis in mice. Hepatology 2013;58:1143-1152.
23. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci U S A 1994;91:12808-12812.
24. Maryanovich M, Oberkovitz G, Niv H, Vorobiyov L, Zaltsman Y, Brenner O, et al. The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat Cell Biol 2012;14:535-541.
25. Marhenke S, Lamle J, Buitrago-Molina LE, Canon JM, Geffers R, Finegold M, et al. Activation of nuclear factor E2-related factor 2 in hereditary tyrosinemia type 1 and its role in survival and tumor development. Hepatology 2008;48:487-496.
26. Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, et al. Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 2005;122:593-603.
27. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A, Korsmeyer SJ. A role for proapoptotic BID in the DNA-damage response. Cell 2005;122:579-591.
28. Kashyap R, Jain A, Nalesnik M, Carr B, Barnes J, Vargas HE, et al. Clinical significance of elevated alpha-fetoprotein in adults and children. Dig Dis Sci 2001;46:1709-1713.
29. Matouk IJ, DeGroot N, Mezan S, Ayesh S, Abu-lail R, Hochberg A, et al. The H19 non-coding RNA is essential for human tumor growth. PLoS One 2007;2:e845.
30. Bulavin DV, Fornace AJ, Jr. p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 2004;92:95-118.
31. Kennedy NJ, Davis RJ. Role of JNK in tumor development. Cell Cycle 2003;2:199-201.
32. Jorquera R, Tanguay RM. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion. Biochem Biophys Res Commun 1997;232:42-48.
33. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK, et al. The BH3-only protein bid is dispensable for DNA damage- and replicative stress-induced apoptosis or cell-cycle arrest. Cell 2007;129:423-433.
34. Khodthong C, Ismaili I, Juckem L. The impact of transfection mediated toxicity-gene expression and cytotoxicity analysis of transfection reagents. 2012. Available at: https://www.mirusbio.com/assets/misc_technical_documents/the_impact_of_transfection_mediated_toxicity.pdf. Accessed May 30, 2015.
35. Johnson WT, DeMars LC. Increased heme oxygenase-1 expression during copper deficiency in rats results from increased mitochondrial generation of hydrogen peroxide. J Nutr 2004;134:1328-1333.
36. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007;11:191-205.
37. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, et al. p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 2007;39:741-749.
38. Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT. Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 2012;42:1295-1301.
39. Rudalska R, Dauch D, Longerich T, McJunkin K, Wuestefeld T, Kang TW, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-1146.